Is the Russian clinical literature legitimate?

It is peer-reviewed and PubMed-indexed. The difficulty is access and independent assessment, not existence. Treat it as evidence that is hard to verify rather than as evidence that is absent.

Are there Western clinical trials of Semax?

No substantial Western clinical programme exists, and no Western regulator has reviewed it.

Which paper is the best starting point?

The 2006 Brain Research study on BDNF and trkB expression, PMID 16996037, is the most cited mechanistic entry point.

Semax (ACTH Fragment Peptide)

Semax in the Published Literature

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-234 cited sources

PubMed indexes roughly 231 Semax records. The mechanistic literature appears in international journals including Brain Research and BMC Genomics and is conducted almost entirely in rats. The clinical literature is concentrated in Russian-language journals, principally the Korsakov Journal of Neurology and Psychiatry.

Key facts

Indexed PubMed records: ~231
Mechanistic work: Predominantly rat models
International journals: Brain Res, BMC Genomics, J Mol Neurosci
Clinical work: Largely Russian-language
Principal clinical journal: Zh Nevrol Psikhiatr Im S S Korsakova
Earliest clinical records: Late 1990s
Western regulatory review: None

Two literatures, not one

Semax's evidence base splits unusually cleanly. Mechanistic and preclinical work appears in international peer-reviewed journals and is accessible in English — the BDNF and trkB study in Brain Research, the focal-ischaemia transcriptomics in BMC Genomics, the neurotrophin dynamics work in the Journal of Molecular Neuroscience. Clinical work is concentrated in Russian-language publications, indexed on PubMed by title translation but frequently without accessible English full text.

What that means for assessment

It creates an asymmetry. A reader can evaluate the preclinical mechanistic claims directly, because the papers are available and the methods are described in a language and format they can check. The clinical claims are harder to assess independently — not because the work does not exist, but because language and access barriers sit between the reader and the methods. Neither dismissing it nor accepting it uncritically is defensible.

Research material referenced

Semax 10mg — third-party HPLC tested

View — £24.99

Age of the clinical record

Records on Semax in ischaemic stroke appear from the late 1990s, with further work published subsequently. Trials from that period generally predate current standards for pre-registration, estimand specification and reporting. That is a statement about when the work was done rather than a judgement of the investigators.

Scale, in context

231 records is a modest literature. For comparison, BPC-157 and TB-500 have accumulated comparable or larger bodies of work, while a widely used approved medicine typically has thousands. Around a decade of concentrated attention plus a longer tail of Russian institutional research produces a body of evidence that is real but not deep.

How to search it

PubMed indexes the field under 'Semax'. Filtering to English-language records isolates the internationally published mechanistic work; removing that filter reveals how much of the clinical record sits outside it. Comparing the two counts is itself informative about the shape of the evidence.

Extended research context

The Semax (ACTH Fragment Peptide) deep dive

Deep dive: what the Pro-Gly-Pro extension actually accomplishes

Semax is built from a four-residue fragment of ACTH with Pro-Gly-Pro appended, and that appendix does two separate jobs at once. Proline is the only proteinogenic amino acid whose side chain bonds back to its own backbone nitrogen, forming a ring that removes the amide hydrogen and locks rotation. Proteolytic enzymes generally need an extended, rotatable backbone at their active site, so bonds near proline are poor substrates for most of them — which is why proline-rich motifs recur throughout stabilised peptide design. The second job is subtractive: Pro-Gly-Pro occupies the positions where ACTH carries Arg-Trp-Gly, and those are the residues contributing to the parent hormone's adrenal-stimulating activity. One substitution therefore buys protease resistance and removes an unwanted pharmacology, which is unusually economical design.

Deep dive: the naming point worth getting right

Semax is near-universally described as an ACTH(4-10) analogue, and peer-reviewed paper titles use that phrase. Structurally it is not quite that. ACTH residues 4 to 10 are Met-Glu-His-Phe-Arg-Trp-Gly; Semax is Met-Glu-His-Phe-Pro-Gly-Pro. The first four residues match and the last three are wholly different — replacement rather than modification. PubChem, indexing by structure rather than design lineage, records it as ACTH(4-7) plus Pro-Gly-Pro. Neither name is wrong, but the loose one obscures the fact that the substituted segment is precisely the functionally consequential part.

Deep dive: reading an unevenly distributed evidence base

Semax's roughly 231 indexed records split along an unusual line. Mechanistic work — BDNF and trkB expression in rat hippocampus, transcriptomics in focal cerebral ischaemia, neurotrophin dynamics across brain regions — appears in international journals in English and can be assessed directly. Clinical work is concentrated in Russian-language publications, principally the Korsakov Journal of Neurology and Psychiatry, indexed by translated title and often without accessible English full text, much of it predating current standards for pre-registration and reporting. The honest position is that this is evidence which is difficult to verify independently, which is a different thing from evidence that is absent, and a different thing again from evidence that is established.

Research applications

▸Neurotrophin expression research (BDNF, NGF, TrkB, TrkA)
▸Neuroprotection and cerebral ischaemia models
▸Study of proline-stabilised peptide design
▸Comparative work on ACTH fragments without steroidogenic activity
▸Transcriptomic profiling in rodent brain models

Handling checklist

✓Store lyophilised material cold, dry and protected from light
✓Expect methionine oxidation as the degradation route (+16 Da; only one Met, so not +32)
✓No reducing agent needed — the sequence contains no cysteine
✓Introduce diluent gently against the vial wall; swirl rather than shake
✓Aliquot to avoid repeated freeze-thaw cycles
✓Check whether a certificate reports net peptide content or gross salt weight

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Describing Semax as ACTH(4-10) without qualification

Fix: It shares only residues 4-7; Pro-Gly-Pro replaces Arg-Trp-Gly, and that replacement is the design's whole point.

✗ Treating Russian registration as equivalent to MHRA approval

Fix: Authorisations are jurisdictional and do not transfer. Semax has never been assessed by the MHRA, EMA or FDA.

✗ Reading a BDNF expression change as a demonstrated outcome

Fix: The studies measured gene and protein expression in rats. Expression is upstream of function and upstream again of any clinical claim.

✗ Assuming a named receptor exists

Fix: No primary receptor has been definitively established; the literature characterises downstream effects more confidently than the initiating event.

✗ Expecting ACTH-like adrenal effects

Fix: Semax does not stimulate adrenal steroidogenesis — the responsible residues were substituted out.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

Is the Russian clinical literature legitimate?: It is peer-reviewed and PubMed-indexed. The difficulty is access and independent assessment, not existence. Treat it as evidence that is hard to verify rather than as evidence that is absent.
Are there Western clinical trials of Semax?: No substantial Western clinical programme exists, and no Western regulator has reviewed it.
Which paper is the best starting point?: The 2006 Brain Research study on BDNF and trkB expression, PMID 16996037, is the most cited mechanistic entry point.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

More Semax (ACTH Fragment Peptide) articles

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum